Welcome to the e-CCO Library!

P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, A. Sitibondo2, M. Cappello3, B. Scrivo3, A. Busacca3, A.C. Privitera4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, N. Belluardo7, E. Giangreco7, C. Bertolami8, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 30 January 2020, 10:12 AM
P325: Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn's disease patients previously treated with infliximab: a large, multicentre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tanaka H.*1, Kamata N.2, Yamada A.3, Fujii T.4, Endo K.5, Yoshino T.6,7, Sugaya T.8, Kawaguchi T.9, Bamba S.10, Ishii M.11, Shinzaki S.12, Toya Y.13, Yanai Y.14, Yokoyama Y.15, Umeno J.16, Okada T.17, Kobayashi T.18, Nojima M.19, Hibi T.18 the ADJUST Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P325: Efficacy, safety, and long-term outcome of endoscopic dilation therapy for stricturing Crohn’s disease of the upper gastrointestinal tract: a combined analysis of 127 endoscopic balloon dilation procedures
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Bettenworth*1, M. M. Mücke1, A. Singh2, R. Lopez3, F. Rieder4, 5

Created: Friday, 22 February 2019, 9:49 AM
P325: Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Jairath*1, K. Lasch2, K. Chan3, S. Kanters4, J. Jansen4, C. Agboton5, H. Patel6

Created: Friday, 22 February 2019, 9:41 AM
P325: Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Mtir, M.(1);Hassine, H.(1);Kahlaoui, F.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P325: Proton pump inhibitors are associated with a disabling course of Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Barrau, M.(1)*;Duru, G.(2);Nancey, S.(3);Phelip, J.M.(4);Cheifetz, A.(5);Papamichael, K.(5);Paul, S.(6);Xavier, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P325: Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Parakkal, D.(1);Johnson, A.(2);Fenster, M.(3);Ramos, G.(2);Zulqarnain, M.(4);Ullman, T.(3);Huang, L.(1);Gutierrez, A.(1);Bruss, A.(4);Ungaro, R.(5);Cohen, B.(6);Gaurav, S.(7);Anish, P.(8);Sasankan, P.(6);Costable, N.(5);Pekow, J.(9);Wang, W.(9);Rubin, D.(9);Ciorba, M.(1);Beniwal-Patel, P.(4);Loftus, E.(2);Yarur, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P325: Risk factors for lymph node involvement in patients undergoing ileal pouch-anal anastomosis for ulcerative colitis complicated by colorectal cancer in the biological years
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Rottoli1, F. Ghignone1*, M. Tanzanu1, L. Boschi1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

Created: Thursday, 21 February 2019, 9:14 AM
P326 Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Mahmmod1, J.P.D. Schultheiss1, A.C.I.T.L. Tan2, M.W.M.D. Lutgens3, L.P.L. Gilissen4, N. Mahmmod5, A.E. van der Meulen - de Jong6, G. Dijkstra7, A.A. van Bodegraven8, B. Oldenburg1, H.H. Fidder1

Created: Thursday, 30 January 2020, 10:12 AM
P326: An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States
Year: 2021
Source: ECCO'21 Virtual
Authors: Ungaro, R.(1);Chou, B.(2);Mo, J.(3);Ursos, L.(4);Twardowski, R.(5);Candela, N.(6);Colombel, J.F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P326: Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schmidt C.*1, Langbein C.1, Atreya R.2, Bruns T.1, Dignass A.3, Ende K.4, Hampe J.5, Hartmann F.3, Neurath M.F.2, Maul J.6,7, Preiss J.C.7, Schmelz R.5, Siegmund B.7, Schulze H.3, Teich N.8, van Arnim U.9, Baumgart D.C.10, Stallmach A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P326: Physicians’ recommendations for travel in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

W.P.W. Chan1,2, H.H. Shim2, S.C. Ng3, Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group, J. Liu1, C. Inglis1, K. Greveson4, R.W. Leong1*

Created: Thursday, 21 February 2019, 9:14 AM
P326: PREFAB-study: PRediction tool for Early identification of patients at risk of Crohn's disease in perianal Fistulas and ABscesses: interim analysis of a prospective pilot study at a non-academic, IBD-expert centre in the Netherlands
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Munster, L.(1)*;de Groof, E.J.(1);van Dieren, S.(2);Mundt, M.W.(3);D'Haens, G.R.A.M.(4);Bemelman, W.A.(5);Buskens, C.J.(5);van der Bilt, J.D.W.(1);
Created: Friday, 14 July 2023, 11:05 AM
P326: The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Mckirdy, S.(1);Russell, R.(2);Hansen, R.(3);Svolos, V.(1);Gkikas, K.(1);Logan, M.(1);Gerasimidis, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P326: Validation of CUCQ-8 Questionnaire for Quality of Life Assessment in IBD Patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. McGinley*1, C. Mowat2, M. Groome2, J. Todd2, N. Reynolds2

Created: Friday, 22 February 2019, 9:49 AM
P327 Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Rundquist1, M. Sachs2, C. Eriksson1, O. Olén3, S. Montgomery4, J. Halfvarson1, SWIBREG Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P327: Biosimilar infliximab in real-life Crohn’s disease’s anti-TNFalfa naïve patients: a comparative observational cohort study (SIMRECRO study)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Carvalho Lourenço*, V. Anapaz, A. M. Oliveira, J. Branco, M. Cardoso, C. Graça Rodrigues, L. Santos, D. Horta, A. Martins, J. Reis

Created: Friday, 22 February 2019, 9:49 AM
P327: Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group
Year: 2023
Source: ECCO’23 Copenhagen
Authors: López García, A.(1)*;Benítez, J.M.(2);Maroto-Martín, C.(3);Fernández-Prada, S.J.(3);Marquina, V.(4);Rodríguez, G.E.(5);Mesonero, F.(6);Lucendo, A.J.(7);Flórez-Díez, P.(8);Casanova, M.J.(9);García-Morales, N.(10);Miranda, J.(11);Vicuña, M.(12);Font, G.(1);Suárez-Ferrer, C.(13);Bernal, L.(14);Peries, L.(15);Mínguez, A.(16);Tejedor, J.(17);Pérez-Galindo, P.(18);Elosua, A.(19);Lastiri, E.A.(20);Brunet, E.(21);Llaó, J.(22);Rodríguez-Lago, I.(23);Ferreiro-Iglesias, R.(24);López, L.(25);González, I.(26);Ortega, S.P.(27);Monsalve, S.(28);Márquez-Mosquera, L.(1);González-Vivó, M.(1);Murciano, F.(1);Zabana, Y.(4);Barreiro-de Acosta, M.(24);
Created: Friday, 14 July 2023, 11:05 AM
P327: Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring
Year: 2022
Source: ECCO'22
Authors: Shields, S.(1);Dunlop, A.(2);Barry, S.(3);Galloway, P.(2);Seenan, J.P.(1);Macdonald, J.(1);
Created: Friday, 11 February 2022, 3:52 PM